计算溶液所需的质量、体积或浓度。
Astegolimab (anti-IL-1RL1) (Ab177886) - ELISA
Immobilized Human-ST2-ECD-his at 2 μg/mL can bind Astegolimab (anti-IL-1RL1) (Ab177886) with the EC₅₀ of 28.29 ng/mL.
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
Ab177886-100μg |
100μg |
现货 ![]() |
| |
Ab177886-1mg |
1mg |
现货 ![]() |
| |
Ab177886-5mg |
5mg |
现货 ![]() |
| |
Ab177886-10mg |
10mg |
期货 ![]() |
|
产品名称 | Astegolimab (anti-IL-1RL1), IL-33 受体(ST2)抑制剂 |
---|---|
别名 | 阿斯替格单抗(抗IL-1RL1) |
英文别名 | EC 3.2.2.6 | Protein ST2 |
规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
宿主种属 | 人(Human) |
特异性 | IL1RL1 |
种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
偶联 | Unconjugated |
作用类型 | 抑制剂 |
作用机制 | IL-33 受体(ST2)抑制剂 |
克隆类型 | 重组抗体 |
---|---|
Format | Whole IgG |
亚型 | Human IgG2 |
轻链亚型 | kappa |
SDS-PAGE | 26.1 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 189.3kDa, under non-reducing conditions. |
纯化方法 | Protein A purified |
纯度 | >95% |
物理外观 | Liquid |
储存缓冲液 | Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
防腐剂 | No |
浓度 | 见COA |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
CAS编号和信息 | 2173054-79-8 |
分子类型 | 抗体 |
Astegolimab (anti-IL-1RL1) (Ab177886) - ELISA
Immobilized Human-ST2-ECD-his at 2 μg/mL can bind Astegolimab (anti-IL-1RL1) (Ab177886) with the EC₅₀ of 28.29 ng/mL.
Astegolimab (anti-IL-1RL1) (Ab177886) - SEC
The purity of Astegolimab (anti-IL-1RL1) (Ab177886) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 24-04-03 | Ab177886 |
![]() |
分析证书 | 24-04-03 | Ab177886 |
![]() |
分析证书 | 24-04-03 | Ab177886 |
¥579.90
¥329.90
¥329.90
1. Tominaga S, Yokota T, Yanagisawa K, Tsukamoto T, Takagi T, Tetsuka T. (1992) Nucleotide sequence of a complementary DNA for human ST2.. Biochim Biophys Acta, 1171 (2): (215-8). [PMID:1482686] [10.1021/op500134e] |
2. Tominaga, S i Si and 5 more authors.. (1999) Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM.. Biochemical and biophysical research communications, (14): [PMID:10527832] |
3. Li, H H and 7 more authors.. (2000) The cloning and nucleotide sequence of human ST2L cDNA.. Genomics, (1): [PMID:10936050] |
4. Tago, K K and 6 more authors.. (2001) Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V.. Biochemical and biophysical research communications, (3): [PMID:11478810] |
5. Hillman, R Tyler RT, Green, Richard E RE and Brenner, Steven E SE.. (2004) An unappreciated role for RNA surveillance.. Genome biology, [PMID:14759258] |
6. Marvie, Pierrick P and 10 more authors.. (2010) Interleukin-33 overexpression is associated with liver fibrosis in mice and humans.. Journal of cellular and molecular medicine, [PMID:19508382] |
7. Lingel, Andreas and 7 more authors.. (2009) Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.. Structure (London, England : 1993), (14): [PMID:19836339] |
8. Connolly, Dympna J DJ, O'Neill, Luke A J LA and McGettrick, Anne F AF.. (2013) The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling.. The Journal of biological chemistry, (22): [PMID:23319592] |
9. Liu, Xi X and 7 more authors.. (2013) Structural insights into the interaction of IL-33 with its receptors.. Proceedings of the National Academy of Sciences of the United States of America, (10): [PMID:23980170] |